Form 4: RA Capital Boosts Stake in 89bio with $20.7 Million Investment

RA Capital Management and related entities acquired 1,350,000 shares of 89bio, Inc. at $15.35 per share in an at-the-market offering.

Summary

• RA Capital Management, L.P., along with related entities including RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund, L.P., has reported changes in beneficial ownership of 89bio, Inc. shares.
• On March 4, 2024, they acquired 1,350,000 shares of 89bio common stock at a price of $15.35 per share, totaling approximately $20.7 million.
• The shares were acquired directly from the issuer in an at-the-market offering.
• Following the transaction, RA Capital Healthcare Fund, L.P. directly holds 12,431,584 shares, and RA Capital Nexus Fund, L.P. directly holds 335,364 shares.
• RA Capital Management, L.P., as the investment manager for both funds, along with its general partner RA Capital Management GP, LLC, and managing members Dr. Peter Kolchinsky and Mr. Rajeev Shah, disclaim beneficial ownership except to the extent of their pecuniary interest.
• Dr. Derek DiRocco, a Partner of the Adviser, serves on the Issuer's board of directors.

Sentiment

Score: 7

Explanation: The document indicates a significant investment by a major fund, suggesting confidence in the company's future. However, it's a standard regulatory filing, so the sentiment is moderately positive.

Positives

• RA Capital's increased investment signals confidence in 89bio's prospects.
• The at-the-market offering provides 89bio with additional capital.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders and major shareholders, providing transparency to the market.

Comparison to Industry Standards

• RA Capital's investment is similar to other institutional investments in biotech companies, where firms often take significant stakes to influence company strategy and benefit from potential growth.
• Comparable companies with similar institutional ownership structures include [hypothetical company A] and [hypothetical company B], where major funds hold significant portions of the outstanding shares.

Stakeholder Impact

• Shareholders may view RA Capital's increased stake as a positive signal.
• The investment provides 89bio with additional capital, potentially benefiting employees and enabling further research and development.

Key Dates